Stevens-Johnson Syndrome After Armodafinil Use

J Clin Sleep Med. 2018 May 15;14(5):885-887. doi: 10.5664/jcsm.7132.


We present the case of a 21-year-old woman in whom Stevens-Johnson syndrome (SJS) developed after initiation of armodafinil. Although this rare and life-threatening reaction is listed on armodafinil's label, no cases have been reported in the literature. This case, in addition to an update of the drug's label after post-marketing research, both support the link between armodafinil and SJS. Providers should maintain a high clinical suspicion for SJS when starting therapy to minimize associated morbidity and mortality by discontinuing armodafinil at the onset of first symptoms.

Keywords: Stevens-Johnson syndrome; armodafinil.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Idiopathic Hypersomnia / drug therapy
  • Modafinil / adverse effects*
  • Modafinil / therapeutic use
  • Skin / pathology
  • Stevens-Johnson Syndrome / etiology*
  • Stevens-Johnson Syndrome / pathology
  • Wakefulness-Promoting Agents / adverse effects*
  • Wakefulness-Promoting Agents / therapeutic use
  • Young Adult


  • Wakefulness-Promoting Agents
  • Modafinil